Ipilimumab/nivolumab/pembrolizumabGastroparesis: 3 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1871卷 / 1期

关键词：

D O I：

10.1007/s40278-021-01735-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：216 / 216

相关论文

共 50 条

[1] Ipilimumab/Nivolumab/PembrolizumabHypophysitis: 3 case reports
Reactions Weekly, 2024, 2037 (1) : 222 - 222
[2] Ipilimumab/nivolumab/vemurafenibUveitis: 3 case reports
Reactions Weekly, 2016, 1606 (1) : 93 - 93
[3] Ipilimumab/nivolumab/pembrolizumabSarcoidosis: 3 case reports
Reactions Weekly, 2017, 1678 (1) : 109 - 109
[4] Ipilimumab/nivolumab/pembrolizumabMyocarditis: 3 case reports
Reactions Weekly, 2022, 1909 (1) : 303 - 303
[5] Ipilimumab/nivolumab/pembrolizumabThyroiditis: 3 case reports
Reactions Weekly, 2019, 1748 (1) : 268 - 268
[6] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: 3 case reports
Reactions Weekly, 2019, 1751 (1) : 221 - 221
[7] Ipilimumab/nivolumab/pembrolizumabEndocrine toxicities: 3 case reports
Reactions Weekly, 2022, 1912 (1) : 253 - 253
[8] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: 3 case reports
Reactions Weekly, 2018, 1710 (1) : 180 - 180
[9] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: 3 case reports
Reactions Weekly, 2021, 1861 (1) : 175 - 175
[10] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: 3 case reports
Reactions Weekly, 2021, 1840 (1) : 228 - 228

← 1 2 3 4 5 →